MCID: PCH007
MIFTS: 39

Pouchitis

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Pouchitis

MalaCards integrated aliases for Pouchitis:

Name: Pouchitis 58 54 17 71

Characteristics:

Orphanet epidemiological data:

58
pouchitis
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

MESH via Orphanet 44 D019449
UMLS via Orphanet 72 C0376620
Orphanet 58 ORPHA217067
UMLS 71 C0376620

Summaries for Pouchitis

MalaCards based summary : Pouchitis is related to ileitis and colitis. An important gene associated with Pouchitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and Pertussis. The drugs Ciprofloxacin and Vedolizumab have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung.

Wikipedia : 74 Pouchitis is inflammation of the ileal pouch (an artificial rectum surgically created out of ileal gut... more...

Related Diseases for Pouchitis

Diseases related to Pouchitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 ileitis 30.9 TLR4 NOD2
2 colitis 30.6 TLR4 NOD2 CXCL8
3 ulcerative colitis 30.4 TLR4 NOD2 IL1RN CXCL8
4 crohn's colitis 30.2 NOD2 CXCL8
5 sclerosing cholangitis 30.0 TLR4 NOD2 CXCL8
6 cholangitis 30.0 TLR4 NOD2 CXCL8
7 spondylitis 30.0 NOD2 IL1RN
8 exanthem 29.8 IL1RN CXCL8
9 pyoderma 29.7 NOD2 IL1RN CXCL8
10 pyoderma gangrenosum 29.7 NOD2 IL1RN CXCL8
11 crohn's disease 29.6 TLR4 S100A9 NOD2 CXCL8
12 proteasome-associated autoinflammatory syndrome 1 29.4 TLR4 IL1RN CXCL8
13 appendicitis 29.0 TLR4 S100A9 CXCL8
14 arthritis 29.0 TLR4 NOD2 IL1RN CXCL8
15 spondyloarthropathy 1 29.0 TLR4 S100A9 NOD2 IL1RN
16 inflammatory bowel disease 28.6 TLR4 S100A9 NOD2 LTF IL1RN CXCL8
17 irritable bowel syndrome 28.6 TLR4 CXCL8
18 familial adenomatous polyposis 10.8
19 cholangitis, primary sclerosing 10.5
20 overgrowth syndrome 10.5
21 diarrhea 10.4
22 papillomatosis, confluent and reticulated 10.4
23 peripheral nervous system disease 10.3
24 neuropathy 10.3
25 pediatric ulcerative colitis 10.3
26 cytomegalovirus infection 10.3
27 aortitis 10.2 NOD2 IL1RN
28 mevalonic aciduria 10.2 NOD2 IL1RN
29 panuveitis 10.2 NOD2 IL1RN
30 periodic fever, familial, autosomal dominant 10.2 NOD2 IL1RN
31 familial cold autoinflammatory syndrome 10.2 NOD2 IL1RN
32 proctitis 10.2
33 cluster headache 10.2
34 cytokine deficiency 10.2
35 alzheimer disease 17 10.1 S100A9 IL1RN
36 spondylarthropathy 10.1 TLR4 NOD2
37 acute diarrhea 10.1 S100A9 LTF
38 neisseria meningitidis infection 10.1 TLR4 IL1RN
39 hidradenitis 10.1 TLR4 NOD2
40 hidradenitis suppurativa 10.1 TLR4 NOD2
41 deficiency anemia 10.1
42 collagenous colitis 10.1
43 diversion colitis 10.1
44 megacolon 10.1
45 uveitis 10.1
46 iritis 10.1
47 toxic megacolon 10.1
48 adenocarcinoma 10.1
49 colonic disease 10.1
50 gastroduodenitis 10.1

Graphical network of the top 20 diseases related to Pouchitis:



Diseases related to Pouchitis

Symptoms & Phenotypes for Pouchitis

Drugs & Therapeutics for Pouchitis

Drugs for Pouchitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2 Vedolizumab Approved Phase 4 943609-66-3
3 Gastrointestinal Agents Phase 4
4 Cytochrome P-450 Enzyme Inhibitors Phase 4
5 Topoisomerase Inhibitors Phase 4
6 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
7
Adalimumab Approved Phase 3 331731-18-1 16219006
8
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
9
Metronidazole Approved Phase 3 443-48-1 4173
10
Ustekinumab Approved, Investigational Phase 3 815610-63-0
11
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
12
Alicaforsen Investigational Phase 3 185229-68-9 16197724
13 Liver Extracts Phase 3
14 Anti-Inflammatory Agents Phase 3
15 Cholagogues and Choleretics Phase 2, Phase 3
16 Bile Acids and Salts Phase 2, Phase 3
17 Dermatologic Agents Phase 3
18 Anti-Infective Agents Phase 3
19 Antiviral Agents Phase 3
20
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
21 Anti-Bacterial Agents Phase 2
22 Antibiotics, Antitubercular Phase 2
23 Antitubercular Agents Phase 2
24
Scopolamine Approved, Investigational 51-34-3, 6533-68-2 5184
25
Infliximab Approved 170277-31-3
26
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
27
Ethanol Approved 64-17-5 702
28
Nitazoxanide Approved, Investigational, Vet_approved 55981-09-4 41684
29
Certolizumab pegol Approved 428863-50-7
30
Inulin Approved, Investigational, Nutraceutical 9005-80-5 24763
31 Defensins
32 Butylscopolammonium Bromide
33 Bifidobacterium
34 Immunoglobulins
35 Antibodies
36 Chicory
37 Antimalarials
38 Antiprotozoal Agents
39 Complement System Proteins
40 Complement Inactivating Agents
41 Complement Factor H
42 Acidophilus
43 Antiparasitic Agents
44 Antirheumatic Agents
45 Immunosuppressive Agents
46 Immunologic Factors

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
2 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
3 Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis. Completed NCT01737983 Phase 4
4 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
5 A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST) Recruiting NCT02790138 Phase 4 Vedolizumab;Ciprofloxacin;Vedolizumab Placebo
6 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
7 Adalimumab (Humira) in the Treatment of Chronic Pouchitis Completed NCT01670240 Phase 3 Adalimumab;Placebo
8 A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects With Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis Completed NCT02525523 Phase 3 Alicaforsen;Placebo
9 Clinical Approaches to Ileal Pouch Dysfunction Completed NCT00293553 Phase 3
10 Prospective Multicenter Randomized Controlled Double-blind Label Study of the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis Recruiting NCT03524352 Phase 3
11 The Role of Secondary Bile Acids in Intestinal Inflammation Recruiting NCT03724175 Phase 2, Phase 3 ursodiol (ursodeoxycholic acid, UDCA)
12 Stelara fOr ChRonic AntibioTic rEfractory pouchitiS (SOCRATES): A Belgian Open Label Multicenter Pilot-study Not yet recruiting NCT04089345 Phase 3 Ustekinumab
13 Relevance of Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus Terminated NCT00237653 Phase 3 Valganciclovir
14 To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis (Pilot Study) Completed NCT02201186 Phase 2
15 The Use of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis-associated Pouchitis Completed NCT02049502 Phase 2
16 A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis Completed NCT00583076 Phase 2 AST-120
17 A Randomized Double-Blind Trial of Perioperative Administration of Probiotics in Colorectal Cancer Patients. Completed NCT00936572 Phase 2
18 Randomized Trial of Fecal Microbiota Transplantation Versus Placebo for the Induction of Remission in Patients With Active Pouchitis Recruiting NCT03545386 Phase 2
19 Double-blinded Randomized Placebo Controlled Study: Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis Active, not recruiting NCT03378921 Phase 2
20 Clotrimazole Enemas for Pouchitis in Children and Adults Suspended NCT00061282 Phase 1, Phase 2 Clotrimazole
21 A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis Terminated NCT00583531 Phase 2 AST-120
22 Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP) Terminated NCT02782325 Phase 1, Phase 2
23 Prevention of Pouchitis With Short-Chain Fructooligosaccharide Therapy, A Double-Blind, Placebo-Controlled Trial Active, not recruiting NCT02203955 Phase 1 Short-Chain Fructooligosaccharide;Maltodextrin
24 The Interaction Between the Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis: a Multifactorial Approach Unknown status NCT01202396
25 Microbiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration of Lactobacillus Casei DG After Ileostomy Closure in Ileal Pouch Mucosa Unknown status NCT03136419
26 Pelvic Collections on MRI in Patients With Ileal Pouches, and a Feasibility Study of Dynamic MRI Enema and Defaecating MRI Pouchography Unknown status NCT02925260
27 Title Effect of Microbial Translocation and Supplementation With the Probiotic VSL#3 on Neuro-cognitive Functions of HIV Positive Patients Receiving HAART Unknown status NCT02276326
28 Fecal Microbiota Transplantation for the Treatment of Chronic Pouchitis Completed NCT03538366
29 Fecal Microbiota Transplant (FMT) for Pouchitis Completed NCT02428361 Early Phase 1 Biologically active human fecal material, OpenBiome
30 Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Ileal Pouch-Anal Anastomosis Completed NCT02828410
31 Ileal Pouch-anal Anastomosis or Ileo-rectal Anastomosis for Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis? Completed NCT01798953
32 Critical Assessment of Routine Surveillance of Asymptomatic Patients With Ulcerative Colitis With Ileal Pouch-anal Anastomosis and Risk Factors for Dysplasia - is There a Rationale? Completed NCT01764542
33 Ileal Pouch Salvage and Excision Operations: Indications, Complications and Outcomes Completed NCT03952195
34 Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis Completed NCT02438410
35 A Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Microbial Translocation and Chronic Immune Activation in HIV-infected Malian Women Completed NCT02448238
36 Open-Label Trial of a Prebiotic Preparation Containing Inulin and Oligofructose (Synergy-1) for the Treatment of Mild to Moderate Acute Ulcerative Colitis Completed NCT02093767
37 The Effect of Faecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Multicentre, Placebo-controlled, Randomized, Double Blinded Trial Recruiting NCT04100291
38 Biomarker-based Multidisciplinary Team Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease Recruiting NCT04082559
39 The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease Recruiting NCT01765439
40 Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis: a Phase 2A Clinical Trial Not yet recruiting NCT03526796
41 Epidemiologic, Clinical, Endoscopic and Histological Database of Patients With Inflammatory Bowel Disease (IBD) Not yet recruiting NCT01266538
42 Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study Not yet recruiting NCT04014413
43 Development of an Effective Treatment of Cryptosporidiosis in Bangladeshi Children Not yet recruiting NCT04103216
44 EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment Terminated NCT01582568 Certolizumab

Search NIH Clinical Center for Pouchitis

Genetic Tests for Pouchitis

Anatomical Context for Pouchitis

MalaCards organs/tissues related to Pouchitis:

40
Liver, Colon, Lung, Prostate, Small Intestine, Testes, T Cells

Publications for Pouchitis

Articles related to Pouchitis:

(show top 50) (show all 1451)
# Title Authors PMID Year
1
Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. 54 61
19079235 2008
2
Pouch-ouch. 54 61
18043236 2008
3
The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. 54 61
18085334 2008
4
Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. 54 61
17828776 2007
5
Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients. 54 61
16770571 2007
6
The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. 54 61
16493544 2006
7
Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. 54 61
16437636 2005
8
Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? 54 61
16239841 2005
9
Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. 54 61
15131788 2004
10
Biliary lactoferrin concentrations are increased in active inflammatory bowel disease: a factor in the pathogenesis of primary sclerosing cholangitis? 54 61
9791051 1998
11
Exposing the Achilles Heel of Antibiotic Therapy for Pouchitis Using Microbial Function and Composition. 61
31863743 2020
12
Diet-Microbiome Interactions and the Risk of Pouchitis in Ileal Pouch-Anal Anastomosis. 61
31605607 2020
13
Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. 61
31605691 2020
14
Short-term Results After Totally Robotic Restorative Total Proctocolectomy With Ileal Pouch Anal Anastomosis for Ulcerative Colitis. 61
30768495 2020
15
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. 61
31823641 2020
16
Outcome of Ileal Pouch Anal Anastomosis in Patients with Indeterminate Colitis: A Systematic Review and Meta-analysis. 61
31912129 2020
17
Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? 61
31850563 2020
18
The Structure and Function of the Human Small Intestinal Microbiota: Current Understanding and Future Directions. 61
31344510 2020
19
Impact of preoperative duration of ulcerative colitis on long-term outcomes of restorative proctocolectomy. 61
31760437 2020
20
Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Authors' reply. 61
31850582 2020
21
Antibiotics and probiotics in inflammatory bowel disease: when to use them? 61
31885842 2020
22
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. 61
31301452 2020
23
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. 61
32006212 2020
24
Pouchitis: diagnosis and management. 61
31599752 2020
25
Prolyl Hydroxylase Inhibition Mitigates Pouchitis. 61
31618435 2020
26
The therapy of chronic pouchitis. 61
30623632 2019
27
Faecal Proteases from Pouchitis Patients Activate Protease Activating Receptor-2 to Disrupt the Epithelial Barrier. 61
31056700 2019
28
Mixed Bag: How C. Difficile Can Cause Pouchitis. 61
31828463 2019
29
Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. 61
31579976 2019
30
Lower fecal pH may be a novel indicator of pouchitis after IPAA in patients with FAP or metachronous Lynch syndrome. 61
31478202 2019
31
Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. 61
31187322 2019
32
Adherence to the Mediterranean diet is associated with decreased fecal calprotectin in patients with ulcerative colitis after pouch surgery. 61
31813010 2019
33
Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. 61
31700634 2019
34
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. 61
31606162 2019
35
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. 61
31785173 2019
36
Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. 61
31596761 2019
37
Pouchitis in pediatric ulcerative colitis: A multicenter study on behalf of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition. 61
31324473 2019
38
Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery. 61
31667470 2019
39
A Polymorphism in Interleukin-1β Gene Is Associated with the Development of Pouchitis in Japanese Patients with Ulcerative Colitis. 61
31671425 2019
40
Pouch wall thickness and floppy pouch complex. 61
31650238 2019
41
Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients. 61
31587035 2019
42
Obesity Is Associated with Decreased Risk of Clostridium difficile Infection in Hospitalized Patients with Pouchitis. 61
31617129 2019
43
De Novo Crohn's Disease of the Pouch in Children Undergoing Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. 61
31136563 2019
44
Nutritional approach as therapeutic manipulation in inflammatory bowel disease. 61
31665832 2019
45
Early Experience with Variant Two-Stage Approach in Surgical Management of Inflammatory Bowel Disease Colitis in the Pediatric Population. 61
31403384 2019
46
Pyloric and foveolar type metaplasia are important diagnostic features in Crohn's disease that are frequently missed in routine pathology. 61
31538655 2019
47
Fruit Consumption is Associated with Alterations in Microbial Composition and Lower Rates of Pouchitis. 61
30828722 2019
48
Promise of Fecal Microbiota Transplantation Therapy in Pouchitis. 61
31529413 2019
49
Difference in the frequency of pouchitis between ulcerative colitis and familial adenomatous polyposis: is the explanation in peripouch fat? 61
30985958 2019
50
Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Surgical Intervention versus Immunomodulatory Therapy. 61
31494658 2019

Variations for Pouchitis

Expression for Pouchitis

Search GEO for disease gene expression data for Pouchitis.

Pathways for Pouchitis

Pathways related to Pouchitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.03 TLR4 S100A9 NOD2 LTF IL1RN CXCL8
2 11.25 TLR4 CXCL8
3 11.08 TLR4 CXCL8
4 11.06 TLR4 NOD2 CXCL8
5 10.96 TLR4 CXCL8
6 10.85 IL1RN CXCL8

GO Terms for Pouchitis

Biological processes related to Pouchitis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.81 TLR4 S100A9 NOD2 LTF
2 inflammatory response GO:0006954 9.78 TLR4 S100A9 IL1RN CXCL8
3 positive regulation of JNK cascade GO:0046330 9.63 TLR4 NOD2 IL1RN
4 neutrophil chemotaxis GO:0030593 9.61 S100A9 IL1RN CXCL8
5 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.6 TLR4 NOD2
6 antimicrobial humoral response GO:0019730 9.59 S100A9 LTF
7 positive regulation of tumor necrosis factor production GO:0032760 9.58 TLR4 NOD2
8 toll-like receptor signaling pathway GO:0002224 9.58 TLR4 S100A9
9 regulation of inflammatory response GO:0050727 9.58 TLR4 S100A9 NOD2
10 positive regulation of interleukin-1 beta secretion GO:0050718 9.57 TLR4 NOD2
11 positive regulation of interleukin-8 production GO:0032757 9.56 TLR4 NOD2
12 defense response to bacterium GO:0042742 9.56 TLR4 S100A9 NOD2 LTF
13 positive regulation of interleukin-10 production GO:0032733 9.55 TLR4 NOD2
14 positive regulation of stress-activated MAPK cascade GO:0032874 9.54 TLR4 NOD2
15 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.54 S100A9 LTF CXCL8
16 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.52 TLR4 NOD2
17 positive regulation of interleukin-6 production GO:0032755 9.5 TLR4 NOD2 IL1RN
18 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.49 TLR4 NOD2
19 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.46 TLR4 NOD2 LTF IL1RN
20 cellular response to lipopolysaccharide GO:0071222 9.26 TLR4 NOD2 IL1RN CXCL8
21 positive regulation of NF-kappaB transcription factor activity GO:0051092 8.92 TLR4 S100A9 NOD2 LTF

Molecular functions related to Pouchitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 8.62 TLR4 LTF

Sources for Pouchitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....